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Persistent human papillomavirus infection (HPV) is recognized as an important etiologic factor for a subset of head
and neck squamous cell carcinomas (SCC), especially those arising from the oropharynx. Whereas HPV16 accounts
for the majority of HPV DNA-positive oropharyngeal SCC, infections with other mucosal high-risk HPV types are
quite rare and biological data demonstrating their causal involvement are insufficient. Here we present the first case
of an oropharyngeal SCC driven by HPV type 58. A 69-year-old Caucasian woman presented with an enlarged and
firm left tonsil. A computed tomography scan showed a left tonsillar mass, extending to the soft palate and the
glossotonsillar sulcus. The patient underwent extended radical tonsillectomy and ipsilateral selective neck dissection.
Pathology confirmed an infiltrating, poorly differentiated SCC of the left tonsil with node metastasis (pT2N1). Adjuvant
external beam radiation therapy (60 Grays (Gy)) was administered. After 1 year of follow-up, the patient is well with no
evidence of cancer recurrence. HPV analyses of the tumor tissue by BSGP5+/6+ −PCR/MPG, targeting 51 mucosal HPV
types, showed single positivity for HPV type 58. Presence of HPV58 E6*I RNA demonstrated biological activity of the
virus in the tumor tissue, and presence of serum antibodies to HPV58 oncoproteins E6 and E7 indicated presence of an
HPV58-driven cancer. Overexpression of cellular protein p16INK4a and reduced expression of pRb, two cellular markers
for HPV-induced cell transformation, were observed. Exons 4–10 of TP53 showed no mutations or polymorphisms. The
presence of HPV58 as single HPV infection in combination with a broad variety of direct and indirect markers of HPV
transformation provides comprehensive evidence that this oropharyngeal SCC was driven by HPV58.
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Oropharyngeal squamous cell carcinomas (OPSCC) are
categorized as head and neck squamous cell carcinoma
(HNSCC) together with squamous cell carcinoma of the
oral cavity, larynx and hypopharynx. OPSCC account for
approximately 50,000 incident cases [1,2], and together
with hypopharyngeal squamous cell carcinomas they
account for about 1.1% of all malignancies worldwide
[3]. Tobacco smoking and alcohol consumption are
recognized as major risk factors but infection with Human* Correspondence: annarosa.delmistro@ioveneto.it
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reproduction in any medium, provided the orpapillomaviruses (HPV) has been identified as a causal
factor for an increasing number of OPSCC, particularly in
Waldeyer’s tonsillar ring [4,5].
Among the 51 mucosal HPV types known so far, 12
have been classified as carcinogenic (class I) for cervical
cancer (CxCa) [6]. While HPV type 16 is the most
prevalent type in CxCa worldwide (61%), the other
carcinogenic types, i.e. HPV18, 31, 33, 35, 39, 45, 51, 52,
56, 58 and 59 (here referred to as non-HPV16 types) are
responsible for approximately another 33% of CxCa,
with HPV58 specifically accounting for 2% of CxCa.
HPV58 in cervical cancer has the highest prevalence
in Asia (4%), followed by North- and South-America
(2% each), Europe (1%) and Africa (<1%) [7].Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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DNA-positive OPSCC are associated with HPV16 (89% -
97%), and DNA of other carcinogenic non-HPV16 types
has been detected only rarely in OPSCC tissues [8-10]. A
recent metanalysis of HPV DNA prevalence in head and
neck cancers (Ndiaye C, Alemany L et al., in preparation)
identified 11 (0.8%) HPV58 DNA positives among a total of
1466 HPV DNA positive oropharyngeal cancer cases that
had been analysed for presence of HPV58 DNA [5,11-15].
Intriguingly, only a subset of HPV16 DNA-positive
OPSCC display HPV16 carcinogenic activity in the
tumor tissue, i.e. are HPV-driven (HPV DNA-positive
RNA-positive) OPSCC, particularly in populations with
low HPV DNA prevalence in OPSCC such as Western
Europe. This indicates that presence of HPV DNA alone
is not sufficient proof for causal involvement of any
HPV DNA found in an OPSCC tissue. For non-HPV16
types found in OPSCC molecular proof of causality is
largely lacking.
Over the last 25 years a rather detailed model of
HPV-driven transformation of human tumor cells has
been established. Truly HPV-transformed tumor cells
contain at least one viral genome copy per cell and
express the viral oncogenes E6 and E7. Interaction of
the E6 and E7 oncoproteins with key regulators of cell
cycle and apoptosis leads to upregulation of cellular protein
p16INK4a and downregulation of tumor suppressor
proteins pRb and p53. In patients with invasive HPV-driven
cervical, penile and oropharyngeal SCC overexpression of
E6 and E7 oncoproteins frequently leads to strong antibody
responses against these viral proteins [4,16-24].
This model has been extensively verified in cervical
carcinoma for all HPV types classified by IARC/WHO
as carcinogenic, probably and possibly carcinogenic [25].
It has also been fully or partially verified for HPV16 in
squamous cell carcinoma of the oropharynx [8,26],
larynx [27], oral cavity [28], penis [17] and anus [29].
Here, we present the first case of an OPSCC driven by
HPV58, a carcinogenic HPV type with low prevalence in
CxCa, as demonstrated by a broad variety of HPV
transformation markers. The present case is part of
an ongoing prospective multicentric study of head
and neck cancer patients from North-East Italy.
Case presentation
Clinical data
A 69-year-old Caucasian woman presented with a 2 months
history of foreign-body sensation in the throat. She had a
negative history for tobacco and alcohol use. The patient
underwent regular gynecological examinations and cyto-
logical cervical cancer screenings until the age of 64, and
no HPV-associated genital lesions or cytological alterations
were found. No anogenital tumor had become symptomat-
ically apparent since then and extending also into thefollow-up period after treatment of the index throat condi-
tion. The patient got infected with hepatitis B virus (HBV)
by blood transfusion at the age of 26, and had been treated
for lichen ruber planus in the oral cavity at the age of 34.
The ENT (Ear Nose and Throat) physical examination re-
vealed an enlarged left tonsil without ulceration. On palpa-
tion, the left tonsil was found to be firm to hard in
consistency. She did not have any palpable cervical lymph-
adenopathy. A computed tomography (CT) scan with con-
trast of the neck confirmed a left tonsillar lesion of 20 ×
23 × 26 mm in dimension, extending up to the soft palate,
without crossing midline, and down to the glossotonsillar
sulcus, and revealed two homogeneously enhancing lymph
nodes, with maximum transverse diameters of 13 mm, in
the left submandibular triangle. Baseline investigations in-
cluding complete and differential blood cell count, serum
electrolytes, liver and renal function tests, electrocardio-
gram, and X-ray chest, were well within normal limits.
The patient underwent wedge biopsy of the left tonsillar
mass. Pathologic review revealed the presence of a poorly
differentiated SCC with basaloid features.
The patient underwent left side mandibulotomy,
extended radical tonsillectomy and ipsilateral selective
neck dissection (levels I-II-III-IV). The surgical defect
was reconstructed with a microvascular ulnar forearm
flap. Final pathology confirmed an infiltrating, poorly-
differentiated SCC of the left tonsil, with tumor measuring
28 mm in greatest dimension and a thickness of 14 mm,
abundant comedo-type necrosis and the presence of both
vascular and perineural invasion. Histopathological
examination of the neck dissection tissue showed an
enlarged lymph node with intracapsular metastasis at
level II (pT2N1). To minimize the risk of locoregional
recurrence the treatment was completed with adjuvant
external beam radiation therapy (EBRT), which started
7 weeks after surgery. Radiation treatment targeted
the tonsillar bed and the left cervical region. A dose
of 60 Gy was delivered with conventional fraction-
ation (2 Gy/fraction, once daily, five times weekly).
The HPV molecular data were not available at the
time of clinical diagnosis and tumor treatment. After
1 year of follow-up, the patient is well with no evidence of
recurrent cancer.Molecular analyses
Analyses were performed in fresh-frozen tumor biopsy,
formalin-fixed paraffin-embedded (FFPE) tumor tissue
and serum. All samples were collected at the time of initial
tumor diagnosis before surgery and radiotherapy.
Genomic DNA was extracted from sections of fresh-
frozen and FFPE tissues following previously described
procedures [8,25,30]. More than 80% of the cells in he-
matoxylin eosin-stained adjacent sections were neoplastic.
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MPG [31-33], an assay capable of amplifying about 150
base pairs (bp) of the L1 gene of 51 HPV mucosal types,
followed by hybridization to type-specific probes on
fluorescent suspension array beads. It includes detection
of the human β-globin gene as DNA quality control
as well as internal PCR and hybridization controls.
Sample DNA was also analyzed by MY09/11-PCR
amplification followed by both Restriction Fragment Length
Polymorphism (RFLP) analysis and direct sequencing [34].
Genomic DNA extracted from both fresh-frozen and
FFPE tumor tissues contained HPV58 as single mucosal
HPV infection, as shown by both mucosal HPV genotyping
methods.
Total RNA was obtained from FFPE tissue sections
using the Pure-Link FFPE Total RNA Isolation Kit
(Invitrogen, Carlsbad, CA) following the manufacturer’s
protocol. Viral RNA expression was analyzed by E6*I
reverse transcription (RT)-PCR [25]. Briefly, the HPV
type-specific assay generates 70 bp long cDNA amplicons
across the E6*I splice site that are subsequently detected
by hybridization to type-specific and splice site-specific
probes on fluorescent suspension array beads. A duplex
assay was performed for RNA of HPV16 and the cellular
housekeeping gene ubiquitin C (UbC), and a singleplex
assay for HPV58. The sample was positive for the HPV58
E6*I and UbC transcripts and negative for the HPV16
E6*I transcript.
The HPV antibody status was analyzed by a glutathi-
one S-transferase (GST) capture immunosorbent assay
using as antigens full-length HPV proteins bacterially
expressed as GST fusion proteins [35,36] in combination
with fluorescent suspension array beads as previously
described [4,37,38]. Antibodies to the E6 and E7 oncopro-
teins of high-risk HPV types 16, 18, 31, 33, 45, 52 and 58
and low-risk types 6 and 11 were quantified. Positivity was
high for E6 and E7 of HPV58. Weaker signals were
observed for E7 of the closely related HPV types 31 and
33 and are interpreted as cross-reactivity with the HPV58
E7 protein (Figure 1).
The expression level of the cellular proteins p16INK4a
and pRb, markers for HPV transformation, were evalu-
ated by immunohistochemistry (IHC). The monoclonal
antibodies CINtec (V-kit, MTM laboratories, Heidelberg,
Germany) and NCL-RB (Novocastra, Newcastle, UK),
were used for p16INK4a and pRb, respectively. Well
characterized sections from CxCa and a healthy mucosa
were used in each staining batch as reference for scoring
of the protein expression levels for both markers. IHC
was evaluated independently by two investigators. The
tumor cells of the sections showed strong nuclear and
diffuse cytoplasmic staining of p16INK4a (>95%) and low
staining of pRb (<25%), while proliferating basal and
parabasal cells of the tumor-adjacent mucosa showedlow p16INK4a (<5%) and high pRb (>25%) expression
(Figure 2).
TP53 mutation status was determined in genomic
DNA isolated from the fresh-frozen biopsy. Exons 4–10
were amplified using specific primer pairs for each exon
as described in the IARC protocol [39]. Amplification
products were sequenced using the ABI PRISM® 3730XL
Genetic Analyzer (Applied Biosystems, Foster City, CA).
No mutations or polymorphisms were observed.
Discussion
HPV-driven OPSCC appears to represent a tumor entity
distinct from HPV-negative OPSCC. Patients with
HPV-driven OPSCC in comparison to patients with
HPV-negative OPSCC have a better outcome and overall
survival, independent of treatment regimen [40,41]. These
tumors also have been shown to contain fewer overall
somatic mutations/genetic changes [42]. Furthermore,
while in HPV-negative OPSCC tumor suppressor TP53
mutations are present in up to 100%, such mutations are
absent in HPV-positive OPSCC [42-44]. It therefore
appears to be clinically important for prognosis and
potentially for choice of treatment options to determine
the HPV-status of OPSCC cases.
While for HPV16, the HPV-type most frequently
found in HPV DNA-positive OPSCC, a transforming
role in the pathogenesis of a subgroup of OPSCC has
been thoroughly demonstrated [8,16,45], this evidence is
largely lacking for non-16 HPV types that are found in
only 3-14% of OPSCC by HPV genotyping studies applying
sensitive PCR techniques [9,10]. However, as demonstrated
for HPV16 in several studies, presence of HPV DNA alone
is not sufficient evidence for causal involvement of the
HPV type found [8,22,45-47].
The HPV58-positive OPSCC case we describe here
is, to our knowledge, the first case for which ample
molecular and serological evidence is provided to
demonstrate causal involvement of this rare high-risk
HPV type in the pathogenesis of this carcinoma. In
addition to the presence of HPV DNA in the tumor
tissue, we demonstrate (i) presence of HPV58 E6*I
RNA encoding the viral oncoprotein E7, which in
HPV58-positive cervical carcinoma is a consistent marker
of biological activity of the virus [27]; (ii) strong serum
antibody response to both HPV58 oncoproteins E6 and E7;
HPV type concordant E6 and E7 double antibody positivity
has been demonstrated to be highly associated and specific
for invasive HPV-associated cancers with an extremely
low prevalence of about 0.1% in tumor-free individuals
[4,18,21] and to be strongly associated (odds ratios of
44 to 180) with invasive cancer of the cervix [20], the
penis [17] and the upper aerodigestive tract [4,18,21];
(iii) overexpression of p16INK4a and reduced expres-

















HPV E6 and E7 proteins
Figure 1 E6 and E7 antibodies status for HPV58 and other HPV types (16, 18, 31, 33, 45, 52, 6 and 11). MFI (Mean Fluorescence Intensity)
values (y axis) are shown for the early proteins E6 and E7 of HPV58 and other HPV types (16, 18, 31, 33, 45, 6, 11) (x axis). Left: E6 and E7 MFI
values for HPV58; Center and right: the MFI values for the other HPV types tested, grouped as E6 and E7, respectively.
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[26] and also HPV58-transformed cervical cancers
[25,48], and finally (iv) wildtype sequence of TP53, a
marker strongly associated with HPV16-positive OPSCC
[42]. We further excluded the possibility of HPV16 in-
volvement by demonstrating absence of HPV16 DNA, of
HPV16 E6*I RNA and of HPV16 E6 and E7-specific anti-







Figure 2 Immunohistochemistry of cellular proteins p16INK4a and pRb
(M) and in tumor (T) tissue, respectively. B and D, pRb expression in norma
Original magnification 10×. p16INK4a low in the normal tumor-adjacent mu
(C)). pRb high in normal tumor-adjacent mucosa (brown-stained nuclei (B)in HNSCC, multicentric studies are needed to evaluate
the survival of the patient(s) to confirm the better progno-
sis like it was shown for HPV16-positive cases.
Conclusion
This HPV58-driven oropharyngeal carcinoma is the first
well-documented case of HPV transformation in the





. A and C, p16INK4a expression in normal tumor-adjacent mucosa
l tumor-adjacent mucosa and in tumor tissue, respectively. S, stroma.
cosa (blue-stained nuclei (A)), high in the tumor (brown stained nuclei
), low in the tumor (blue-stained nuclei (D)).
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